Compare Regeneron Pharmaceuticals Inc (REGN) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Snap On Incorporated — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Snap On Incorporated trades at $407.92 (market cap $20.93B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 3.4× Snap On Incorporated's market cap, and Snap On Incorporated pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| REGN | SNA | |
|---|---|---|
Market Cap | $70.79B | $20.93B |
Sector | Health | Technology |
52-Week High | $812.27 | $414.97 |
52-Week Low | $545.46 | $317.79 |
Enterprise Value | $64.74B | $20.45B |
Dividend Yield | 0.56% | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Snap-on Incorporated (SNA) trades at $406.53, down 1.09% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $407.50. The company reported strong 2025 results with $5.16B revenue and $1.02B net income, maintaining robust profitability margins. Recent strategic acquisitions like Diesel Laptops for $100M aim to expand its heavy-duty diagnostics capabilities, supporting future growth.
The outlook is positive given solid fundamentals and analyst support, but risks include potential margin pressures and reliance on automotive demand. With 64.71% of analysts rating it a buy and a dividend yield supported by recent declarations, SNA presents a stable investment opportunity tempered by industry cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
